Page last updated: 2024-11-07

n(g)-aminoarginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(G)-aminoarginine: potent antagonist of L-arginine-mediated endothelium-dependent relaxation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124357
CHEMBL ID405231
CHEMBL ID1185292
CHEBI ID191152
SCHEMBL ID18532015
MeSH IDM0176224

Synonyms (19)

Synonym
57444-72-1
omega-aminoarginine
CHEMBL405231 ,
ng-amino-l-arginine
CHEBI:191152
(2s)-2-amino-5-[[amino(hydrazinyl)methylidene]amino]pentanoic acid
AKOS006336939
bdbm50374677
n(g)-aminoarginine
l-ornithine, n5-(hydrazinoiminomethyl)-
CHEMBL1185292
omega-amino-l-arginine
SCHEMBL18532015
n'''-amino-l-arginine
ng -amino-l-arginine
n5 -(hydrazino-iminomethyl)-l-ornithine
NCHSYZVVWKVWFQ-BYPYZUCNSA-N
DTXSID30972923
n~5~-[hydrazinyl(imino)methyl]ornithine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response analysis indicated that L-NNA was 87 and 230 times more potent than L-NMA and L-NAA, respectively."( Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.
Chaudhuri, G; Cuevas, JM; Ignarro, LJ; Vargas, HM, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
arginine derivativeAn amino acid derivative resulting from reaction of arginine at the amino group, the carboxy group, or the guanidyl group, or from the replacement of any hydrogen of arginine by a heteroatom. The definition normally excludes peptides containing arginine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID730391Selectivity ratio of Ki for bovine eNOS to Ki for rat nNOS2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID730388Selectivity ratio of Ki for mouse iNOS to Ki for rat nNOS2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID730390Inhibition of bovine nNOS2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (76.19)18.2507
2000's3 (14.29)29.6817
2010's2 (9.52)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.12 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]